Congrats to @GlitzaMDPhD and MDACC colleagues for nivo iv and i.t. in melanoma w/leptomening spread—opening the field for more such creative work!!
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results | Nature Medicine nature.com/articles/s41591-0…
Kim Margolin retweeted
The oncologist’s typical clinic day- and then evening
xitter.cf/Yoda4ever/status/15744… – at Yonkers, NY
#Melanoma Symposium, free bit.ly/36Gvpn1
Join@EssnerRick@kmargolin@MLAscierto
Sat Apr30 Fairmont Santa Monica
@vernonsondak@jasonlukemd@alliegrossman @DrSancy
@drsapnapatel@drtrevanfischer@stevenkolkermd & Drs.RKorn,DHoon,PatrickOtt
Kim Margolin retweeted
Thank you, #PaulFarmer, for helping grow a community of physicians pursuing serious study of the social sciences and humanities. Thank you for your example, your wit, and for telling me that it didn't matter if my clinical and historical interests didn't line up.
Thank you for pointing out the insensitive wording “salvage therapy” often used by med oncos—don’t forget too (especially to fellows) that “palliative chemo” is only that if it works, not as a way to assuage insistence of patient and family at end of life
This Post is from an account that no longer exists. Learn more
Kim Margolin retweeted
1 of the upsides of being off the road for 18 months was learning how to stay connected without traveling, both with each other & with you. Join us for a free holiday concert, streaming live from our living room to yours.
Send us your song requests, as we’re crafting our set list
Breathtaking #SITC21 so much work done during worst of covid-Kudos Mary Dean, SITC staff, president @PatrickHwuMD , organizers, prog chair Sharma!
Fantastic job at first (still virtual) #SWOG #melanoma committee meeting by incoming chair @drsapnapatel—lots of new protocols on horizon with great correlates. Next spring in Seattle!!
Nobel Prize in Physics Honors Work on Climate Change nytimes.com/2021/10/05/scien…
Kim Margolin retweeted
Can we all agree CDAs should NOT be needed just get a look at the schema and inclusion criteria of a pharma-sponsored trial?
Involving a hospital lawyer just to look at basic trial information that should already be publicly available is an enormous waste of resources. – at Vermont, USA
Kim Margolin retweeted
Congrats @jasonlukemd Phase 3 KEYNOTE-716
KEYTRUDA, @Merck anti-PD-1, met primary endpoint
(RFS) adjuvant high-risk stage II
melanoma vs placebo. Proud to have contributed @angelesclinic @CSCancerCare @UPMCHillmanCC #melanoma
Kim Margolin retweeted
21/ Finally, thanks to Dan Erkes @antidanimmunity and @SciImmunology for your interest in this work. Working with you has truly been a great experience!
